NEW YORK, Nov 27 – Qiagen and Luminex have agreed to jointly develop consumable kits and assays using Luminex’s Labmap technology, the companies announced Monday.

Under the agreement, Qiagen will market the assay detection products beginning in the third quarter of 2001. Luminex has received an upfront payment for the Labmap technology, and will receive future royalty payments from Qiagen based on the sale of kits and reagents.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.